Aptorum’s Lead Product Gets Patent For Treating Neuroblastoma And Other Types Of Cancer

Aptorum, a clinical-stage biopharmaceutical company, announces that it has been granted a patent for its SACT-1 drug, which is designed to treat numerous different types of cancers. SACT-1 is the lead product which is an orally-available small molecule that targets neuroblastoma. Through its mechanism, SACT-1 can kill tumor cells and suppress the expression of the MYCN protein. The company is focused on the discovery and development of new drugs for the treatment of diseases with unmet medical needs.

Aptorum

Aptorum’s SACT-1 invention is a composition that can prevent or treat the growth of various types of tumors. It can be administered as a combination with other agents or as alone. Darren Lui, the company’s president, says that the patent is another step forward for the company, which has already completed its Phase 1 trial for SACT-1. As for the company, the granted patent supports its efforts to develop SACT-1 as a potential treatment for neuroblastoma. It also allows it to pursue further patent applications for the drug in various countries.